The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor β expression

Molecular and Cellular Biochemistry

Volumn 366, Issue 1-2, 2012, Pages 111-122

  Tu, Zhenzhen ^a   Li, Hui ^a   Ma, Yuxiang ^a   Tang, Bin ^a   Tian, Junmei ^a   Akers, Walter ^b   Achilefu, Samuel ^b   Gu, Yueqing ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

Breast cancer; Estrogen receptor ; MCF 7 cell; Raloxifene; Trichostatin A

Indexed keywords

ANTIESTROGEN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HISTONE DEACETYLASE INHIBITOR; RALOXIFENE; RNA; TRICHOSTATIN A;

ADENOVIRUS INFECTION; ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CANCER; CELL CYCLE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FLOW CYTOMETRY; GENE EXPRESSION; IC 50; NONHUMAN; POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN B; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXAMIC ACIDS; INHIBITORY CONCENTRATION 50; RALOXIFENE; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEINS;

ADENOVIRIDAE;

EID: 84862006182     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-012-1288-9     Document Type: Article

References (44)

1. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 71-85
2. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451-1467
3. Hodges-Gallagher L, Valentine CD, Bader SE, Kushner PJ (2007) Inhibition of histone deacetylase enhances the antiproliferative action on antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells. Breast Cancer Res Treat 105:297-309 (Pubitemid 47596448)
4. Clarke R, Leonessa F, Welch JN, Skaar TC (2001) Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53:25-71 (Pubitemid 32173107)
5. Ring A, Dowsett M (2004) Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11:643-658 (Pubitemid 40065543)
6. Chen SJ, Li H, Durand J, Oparil S, Chen YF (1996) Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation 93:577-584 (Pubitemid 26043619)
7. Jacobsson J, Cheng L, Lyke K, Kuwahara M, Kagan E, Ramwell PW, Foegh ML (1992) Effect of estradiol on accelerated atherosclerosis in rabbit heterotopic aortic allografts. J Heart Lung Transplant 11:1188-1193 (Pubitemid 23014583)
8. Adams MR, Kaplan JR, Koritnik DR, Clarkson TB (1987) Pregnancy-associated inhibition of coronary artery atherosclerosis in monkeys. Evidence of a relationship with endogenous estrogen. Arteriosclerosis 7:378-383
9. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, Clarkson TB (1990) Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 10: 1051-1057
10. Barrett-Connor E (1997) Sex differences in coronary heart disease: why are women so superior? The 1995 Ancel Keys Lecture. Circulation 95:252-264
11. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH (1991) Postmenopausal estrogen therapy and cardiovascular disease: ten-year followup from the Nurses' Health Study. N Engl J Med 325:756-762
12. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1647 (Pubitemid 27510100)
13. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 282:637-645 (Pubitemid 29384151)
14. Jordan VC, Robinson SP (1987) Species specific pharmacology of antiestrogens role of metabolism. Fed Proc 46:1870-1874 (Pubitemid 17075934)
15. Mayo Clinic Women's HealthSource (2006) Raloxifene works as well as tamoxifen in preventing invasive breast cancer. Mayo Clin Women's HealthSource 10:3
16. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S (2007) Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25: 3846-3852 (Pubitemid 47477259)
17. Levy N, Tatomer D, Herber CB, Zhao X, Tang H, Sargeant T, Ball LJ, Summers J, Speed TP, Leitman DC (2008) Differential regulation of native estrogen receptor-regulatory elements by estrodiol, tamoxifen, and raloxifene. Mol Endocrinol 22:287-303 (Pubitemid 351185932)
18. Joung KE, Kim DK, Sheen YY (2004) Antiproliferative effect of trichostatin A and HC-toxin in T47D human breast cancer cells. Arch Pharm Res 27:640-645
19. Thomas S, Munster PN (2009) Histone deacetylase inhibitor induced modulation of antiestrogen therapy. Cancer Lett 280: 184-191
20. Hirokawa Y, Arnold M, Nakajima H, Zalcberg J, Maruta H (2005) Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance. Cancer Biol Ther 4:956-960 (Pubitemid 41598590)
21. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM (2001) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 61:8492-8497 (Pubitemid 33131130)
22. Hartman J, Ström A, Gustafsson J-Å (2009) Estrogen receptor beta in breast cancer - diagnostic and therapeutic implications. Steroids 74:635
23. Bardin A, Boulle N, Lazennec G, Vignonl F, Pujoll P (2004) Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 11:537-551 (Pubitemid 39331282)
24. Margueron R, Duong V, Castet A, Cavailles V (2004) Histone deacetylase inhibition and estrogen signalling in human breast cancer cells. Biochem Pharmacol 68:1239-1246 (Pubitemid 39094290)
25. McKenna NJ, O'Malley BW (2002) Minireview: nuclear receptor coactivators - an update. Endocrinology 143:2461-2465 (Pubitemid 34701305)
26. Marks PA, Richon VM, Rifkind RA (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92:1210-1216 (Pubitemid 30627729)
27. Lin CY, Strom A, Li Kong S, Kietz S, Thomsen JS, Tee JB, Vega VB, Miller LD, Smeds J, Bergh J, Gustafsson JA, Liu ET (2007) Inhibitory effects of estrogen receptor β on specific hormoneresponsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Res 9:R25
28. Greco WR, Faessel H, Levasseur L (1996) The search for cytotoxic synergy between anticancer agents: a case of Dorothy and the ruby slippers? J Natl Cancer Inst 88:699-700
29. Bicaku E, Marchion DC, Schmitt M, Munster PN (2008) Selective inhibition of histone deacetylase 2 silences progesterone receptor mediated signaling. Cancer Res 68:1513-1519 (Pubitemid 351346860)
30. Travaglini L, Vian L, Billi M, Grignani F, Nervi C (2009) Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status. Int J Biochem Cell Biol 41:225-234
31. Zhao C, Lam EW, Sunters A, Enmark E, De Bella MT, Coombes RC, Gustafsson JA, Dahlman-Wright K (2003) Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 22:7600-7606 (Pubitemid 37464093)
32. Rody A, Holtrich U, Solbach C, Kourtis K, von Minckwitz G, Engels K, Kissler S, Gätje R, Karn T, Kaufmann M (2005) Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer 12:903-916 (Pubitemid 41815784)
33. Duong V, Licznar A, Margueron R, Boulle N, Busson M, Lacroix M, Katzenellenbogen BS, Cavaillès V, Lazennec G (2006) ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors. Oncogene 25: 1799-1806
34. Lapidus RG, Ferguson AT, Ottaviano YL, Smith HS, Parl FF, Weitzman SA, Baylin SB, Issa JP, Davidson NE (1996) Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res 2:805-810
35. Ruh MF, Tian S, Cox LK, Ruh TS (1999) The effects of histone acetylation on estrogen responsiveness in MCF-7 cells. Endocrine 11:157-164 (Pubitemid 30013607)
36. Liu Z, Wong J, Tsai SY, Tsai MJ, O'Malley BW (1999) Steroid receptor coactivator-1 (SRC-1) enhances ligand-dependent and receptor-dependent cell-free transcription of chromatin. Proc Natl Acad Sci USA 96:9485-9490 (Pubitemid 29398757)
37. Minucci S, Horn V, Bhattacharyya N, Russanova V, Ogryzko VV, Gabriele L, Howard BH, Ozato K (1997) A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells. Proc Natl Acad Sci USA 94:11295-11300 (Pubitemid 27450992)
38. Shang Y, Myers M, Brown M (2002) Formation of the androgen receptor transcription complex. Mol Cell 9:601-610 (Pubitemid 34273790)
39. Fajas L, Egler V, Reiter R, Miard S, Lefebvre AM, Auwerx J (2003) PPARc controls cell proliferation and apoptosis in an RB-dependent manner. Oncogene 22:4186-4193 (Pubitemid 36876239)
40. Zhao C, Dahlman-Wright K, Gustafsson JA (2008) Estrogen receptor beta: an overview and update. Nucl Recept Signal 6:1-10
41. Jang ER, Lim SJ, Lee ES, Jeong G, Kim TY, Bang YJ, Lee JS (2004) The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene 23:1724-1736 (Pubitemid 38445164)
42. Morishima S, Shibata MA, Ohmichi M, Otsuki Y (2008) Raloxifene, a selective estrogen receptor modulator, induces mitochondria- mediated apoptosis in human endometrial carcinoma cells. Med Mol Morphol 41:132-138
43. Fryar-Tita EB, Das JR, Davis JH, Desotos JA, Green S, Southerland WM, Bowen D (2007) Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies. Anticancer Res 27: 1393-1400
44. Krämer OH, Göttlicher M, Heinzel T (2001) Histone deacetylase as a therapeutic target. Trends Endocrinol Metab 12:294-300 (Pubitemid 33714220)